ReviewClinical parkinsonism & related disorders2026
The neutrophil-to-lymphocyte ratio in Parkinson's disease: a systematic review and meta-analysis of its association with differential diagnosis, severity, and prognosis.
Review in Clinical parkinsonism & related disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and aim: This study aimed to systematically review and meta-analyze the evidence on the association of the neutrophil-to-lymphocyte ratio (NLR) with clinical parameters in Parkinson's disease (PD), specifically its role in group differentiation (from healthy controls and other neurodegenerative diseases), disease severity, and prognosis. Methods: In this study, a systematic review and meta-analysis were performed according to the PRISMA guidelines. A search conducted in PubMed, Embase, Scopus, Web of Science, and Google Scholar up to June 2024 was undertaken, providing observational studies that reported NLR in PD. The random-effects models pooled the mean differences of PD versus controls and PD versus multiple system atrophy (MSA), and pooled for UPDRS subscale correlation coefficients, total UPDRS, and Hoehn & Yahr (H&Y) stage. Constipation, depressive symptomatology, and mild cognitive impairment (MCI) markers were also analyzed. Results: Twenty-eight studies were included. The NLR was significantly higher in patients with PD than in healthy controls (MD, 0.38; 95% CI 0.22-0.53; I Conclusion: NLR is higher in PD and correlates with clinical severity and depressive symptoms, but it does not discriminate PD from MSA or between motor subtypes, and it was not associated with incident mild cognitive impairment in the expected direction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.